{"product_id":"biolegend-502507","title":"Biolegend, 502507, FITC anti-human IFN-γ Antibody, 50μg","description":"\u003cp\u003eInterferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Partially purified, native human IFN-γ\u003cbr\u003e\nFormulation: test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.\u003cbr\u003e\nConcentration: µg sizes: 0.5 mg\/mLtest sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For test size, the suggested use of this reagent for immunofluorescent staining is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For µg size, the suggested use of this reagent for immunofluorescent staining is 0.25 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402\/502404) or purified MD-1 antibody (Cat. No. 507502\/507513) as the capture antibody.Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)\u003cbr\u003e\nProduct Citations: Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed Du Q, et al. 2022. J Virol. 96:e0095922. PubMed Carre C, et al. 2021. iScience. 24:102970. PubMed Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed Zhou Y, et al. 2020. Cell Rep. 31:107574. PubMed Lu T, et al. 2016. PLoS One. 11: 0148044. PubMed Wang F, et al. 2018. Oncogenesis. 7:41. PubMed Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed Preglej T, et al. 2020. JCI Insight. 5(4):. PubMed Hess NJ, et al. 2020. J Immunol. 205:272. PubMed Zuazo M, et al. 2019. EMBO Mol Med. 11(7). PubMed Shokri MR, et al. 2019. Sci Rep. 9:10007. PubMed Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed Fisher J, et al. 2017. Mol Ther. 10.1016\/j.ymthe.2017.03.002. PubMed Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed Zou F, et al. 2021. Mol Ther. 29:1794. PubMed Spencer A, et al. 2014. PLoS One. 9:100538. PubMed Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed Meraviglia S, et al. 2017. Oncoimmunology. 6:e1347742. PubMed Morimoto Y, et al. 2018. Immunity. 49:134. PubMed Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed Yu J, et al. 2019. Oncol Lett. 17:1461. PubMed Hamilton JR, et al. 2021. Cell Reports. 35(9):109207. PubMed Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed Kessler B, et al. 2017. Sci Rep. 7:42791. PubMed Pierce CA, et al. 2020. Sci Transl Med. 12:00. PubMed Lu H, et al. 2020. Am J Reprod Immunol. 83:. PubMed Stein RG, et al. 2019. Cancer Res. 79:1507. PubMed Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed Poulsen L 2012. J Immunol. 189:4431. PubMed Corrado M, et al. 2020. Cell Metab. 32:981. PubMed Vacaflores A, et al. 2017. Mol Immunol. 81:1. PubMed Lo Presti E, et al. 2020. J Leukoc Biol. 108:749. PubMed Rochman Y, et al. 2015. PLoS One. 10:122198. PubMed Kuranda K, et al. 2018. J Clin Invest. 128:5267. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed\u003cbr\u003e\nRRID: AB_315230 (BioLegend Cat. No. 502505) AB_315232 (BioLegend Cat. No. 502507) AB_315231 (BioLegend Cat. No. 502506)\u003cbr\u003e\nStructure: Cytokine; dimer; 20-25 kD (Mammalian)\u003cbr\u003e\nBioactivity: Antiviral\/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.\u003cbr\u003e\nRegulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2\u003cbr\u003e\nGene ID: 3458\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nClone: 4S.B3\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862419361961,"sku":"502507","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-502507","provider":"Iright","version":"1.0","type":"link"}